A Review of Proteases and Antiproteases for Immune Regulation and Potential Therapeutic Application in Pulmonary Fibrosis
Journal of Innate Immunity · 2025
DOI: 10.1159/000547814 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Innate Immunity, 2025. Verfasst von Sara Waqas Ahmed und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Clinical Science, Department of Anaesthesia and Critical Care Medicine, Royal College of Surgeons in Ireland, University of Medicine and He…. Hauptthemen laut MEDLINE: Peptide Hydrolases, Pulmonary Fibrosis, Protease Inhibitors, Lung Diseases, Interstitial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: Interstitial lung diseases (ILDs) or diffuse parenchymal lung diseases are general terms for a group of over 200 conditions that result from the destruction of cells neighbouring the alveoli, leading to extensive inflammation and fibrosis of the lungs. Although different types of ILD have distinct pathophysiology, clinical display, and advancement, many forms drive irreversible pulmonary fibrosis (PF), leading to progressive functional impairment, respiratory failure, and mortality. Summary: Key components of innate immunity include proteases and their cognate inhibitors, which are involved in respiratory homoeostasis. Alterations to the protease-antiprotease balance can lead to pulmonary disease and fibrotic scarring of the lungs, and over the past two decades, there has been a surge in research exploring their effect on the pathogenesis of ILDs. We have evaluated relevant studies regarding these enzymes in the context of lung fibrosis and have discussed prospects for developing novel treatments. This review will place greater emphasis on the overall effect of proteases and antiproteases to the development of PF, as studied using both in vivo and in vitro models. Key Message: Considering the limited therapeutic interventions, continued research on proteolytic enzymes and their inhibitors is required for the development of novel effective treatments for PF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonary Clinical Science, Department of Anaesthesia and Critical Care Medicine, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland, sarawaqasahmed24@rcsi.ie.
- Pulmonary Clinical Science, Department of Anaesthesia and Critical Care Medicine, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland.
- Department of Respiratory Medicine, St. Vincent's University Hospital, Dublin, Ireland.
- School of Medicine, University College Dublin, Dublin, Ireland.
Zitieren
APA
Ahmed, S. W., Gogoi, D., Forde, L., Niu, M., Baird, R., McCarthy, C., Keane, M. P., McGrath, E. E., & Reeves, E. P. (2025). A Review of Proteases and Antiproteases for Immune Regulation and Potential Therapeutic Application in Pulmonary Fibrosis. Journal of Innate Immunity. https://doi.org/10.1159/000547814
Vancouver
Ahmed SW, Gogoi D, Forde L, Niu M, Baird R, McCarthy C, et al. A Review of Proteases and Antiproteases for Immune Regulation and Potential Therapeutic Application in Pulmonary Fibrosis. Journal of Innate Immunity. 2025. doi:10.1159/000547814
BibTeX
@article{Ahmed2025,
author = {Ahmed, Sara Waqas and Gogoi, Debananda and Forde, Luke and Niu, Mengxin and Baird, Rory and McCarthy, Cormac and Keane, Michael P and McGrath, Emmet E and Reeves, Emer Patricia},
title = {A Review of Proteases and Antiproteases for Immune Regulation and Potential Therapeutic Application in Pulmonary Fibrosis},
journal = {Journal of Innate Immunity},
year = {2025},
doi = {10.1159/000547814}
}
EUVIMED